Michael Abramoff, MD, PhD - Founder and Executive Chairman
How Did Digital Diagnostics Come About?
Digital Diagnostics is the brainchild of Michael Abrámoff, MD, PhD. During his training to become an ophthalmologist and retina specialist, he saw that patients with diabetic retinopathy were coming to see him when the disease was already too advanced for them to receive optimal treatment.
“This is so inefficient,” he thought. “There has to be a better way.”
Given his background in machine learning, neuroscience and software development, Dr. Abramoff theorized that a computer might be able to help these patients get diagnosed at an earlier stage when effective treatment was still possible. He began to invent computer algorithms that could create a technology that mimics how clinicians like him make their diagnoses.
From the beginning of his career Dr. Abramoff realized the enormous potential for an “autonomous AI”, which makes a diagnosis without human oversight, to improve quality of care and patient access while lowering cost.
Creating the novel technology that Dr. Abramoff had envisioned required special consideration regarding the safety and accessibility involved in trusting a computer rather than a doctor to make a diagnosis. Ensuring that patients, physicians and the public would trust and accept autonomous AI meant it was crucial to approach the creation of such technology with a focus on developing AI the right way. This led to the founding of what would eventually become Digital Diagnostics’ ethical principles: to maximize the safety, efficacy, and equity of autonomous AI.
Thanks to those principles, and the dedication of Dr. Abramoff and his team, today the autonomous diabetic retinopathy diagnostic solution he had envisioned years ago is a fully developed product called LumineticsCore® (formerly IDx-DR), which has been cleared by the FDA for use in clinical care. Since clearance, Dr. Abramoff continues working to integrate LumineticsCore into the healthcare ecosystem leading to reimbursement with CPT® code 92229, inclusion in the HEDIS quality measures, updated standards of care, and widespread adoption of the system which is currently being used to detect diabetic retinopathy and help prevent blindness in locations around the globe.
Today
Dr. Abramoff continues to push boundaries and is a pioneer for a future where ethics, technology and innovation meet to transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment.